Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a prospective, single-arm clinical study evaluating the efficacy and safety of metformin in inhibiting DNMT3A R882-driven clonal hematopoiesis (CH) in patients with acute leukemia (AL) who are in remission and under follow-up. Patients with DNMT3A R882 mutation (VAF ≥5%) will receive oral metformin for 6 months, with dosage gradually increased to 2000 mg/day. The primary endpoint is the proportion of patients with effective decline in DNMT3A R882 mutation VAF at 6 months. Secondary endpoints include VAF decline at 3 months, relapse-free survival (RFS) at 6 and 12 months, overall survival (OS), cumulative incidence of relapse (CIR), cumulative remission-phase mortality, and adverse event rates. Planned enrollment: 32 participants.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rozpoznana białaczka ostra (potwierdzona badaniem szpiku kostnego)
- •Pacjent w okresie zdrowienia (całkowita remisja) z mutacją DNMT3A R882
- •Wiek co najmniej 14 lat, dowolna płeć
- •Prawidłowe wyniki krwi: wątroba, nerki i serce w normie (testy z ostatnich 7 dni)
- •Podpisana zgoda na udział w badaniu (przez pacjenta lub opiekuna)
✗ Disqualifies
- •Cukrzyca leczona innymi lekami
- •Uczulenie na metforminę
- •Lekarz uzna pacjenta za niespełniającego warunki do udziału
Simplified criteria — AI translation
Trial details
- Minimum age
- 14 Years
- Last updated (source)
- August 10, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Blood Diseases Hospital
Tianjin, China
Trial contact
Hui Wei, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/11/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.